Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.

For the period, total cash was equivalent to $154.5 million -compared to $133.5 million as of December 31, 2021. Net cash used in operating activities was $37.3 million for the nine months ended September 30, 2022, compared to $38.0 million for the same period in 2021.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.